Cholesterol

Cholesterol - References & External links

The references to scientific articles about Cholesterol are not meant to imply that any products treat, cure, or diagnose any disease or human condition. We encourage our audience to do their own research beyond the resources we have provided so your decision is as educated as possible.

• The properties of Amorphophallus Konjac reducing Cholesterol:
  • HO, Hoang Vi Thanh; et al. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. The American journal of clinical nutrition, 2017, 105.5: 1239-1247. PMID:28356275
    Conclusions: Our findings support the intake of ∼3 g KJM/d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively. The information may be of interest to health agencies in crafting future dietary recommendations related to reduction in CVD risk. This study was registered at clinicaltrials.gov as NCT02068248.
  • GALLAHER, Daniel D.; et al. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. Journal of the American College of Nutrition, 2002, 21.5: 428-433. PMID:12356785
    CONCLUSIONS: Serum cholesterol reduction by a chitosan/glucomannan supplement is likely mediated by increased fecal steroid excretion and is not linked to fat excretion.
• The properties of Chitosan reducing Cholesterol:
  • GALLAHER, Daniel D.; et al. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. Journal of the American College of Nutrition, 2002, 21.5: 428-433. PMID:12356785
    CONCLUSIONS: Serum cholesterol reduction by a chitosan/glucomannan supplement is likely mediated by increased fecal steroid excretion and is not linked to fat excretion.
  • HUANG, Haohai; et al. Lipid-Modifying Effects of Chitosan Supplementation in Humans: A Pooled Analysis with Trial Sequential Analysis. Molecular nutrition & food research, 2018, 62.8: 1700842. PMID:29451712
    CONCLUSION: Supplementation with chitosan effectively reduces plasma concentrations of TC and LDL-C. Current evidence indicates daily chitosan supplementation as a candidate for therapeutic lipid management strategies.
• The properties of Inositol reducing Cholesterol:
  • TABRIZI, Reza; OSTADMOHAMMADI, V.; LANKARANI, K. B.; PEYMANI, P.; AKBARI, M.; KOLAHDOOZ, F.; ASEMI, Z. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Lipids in health and disease, 2018, 17.1: 123. PMID:29793496
    CONCLUSIONS: Inositol supplementation may result in reduction in triglycerides, total- and LDL-cholesterol levels, but did not affect HDL-cholesterol levels among patients with metabolic diseases. Additional prospective studies regarding the effect of inositol supplementation on lipid profiles in patients with metabolic diseases are necessary.
• The properties of Zingiber Officinale reducing Cholesterol:
  • POURMASOUMI, Makan; et al. The effect of ginger supplementation on lipid profile: A systematic review and meta-analysis of clinical trials. Phytomedicine, 2018, 43: 28-36. PMID:29747751
    CONCLUSION: The present systematic review and meta-analysis suggests that ginger had a favorable effect on TAG and LDL-C. Also, the result revealed that low dose of ginger (≤2 g/day) had greater lowering impact on TAG and TC. Further studies with large-scale and better design are needed to confirm this result.
• The properties of Pterostilbene reducing Cholesterol:
  • RICHE, K. D.; BLACKSHEAR, C. T.; MCEWEN, C. L.; SHERMAN, J. J.; WOFFORD, M. R.; GRISWOLD, M. E. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evidence-Based Complementary and Alternative Medicine, 2014, 2014: . PMID:25057276
    CONCLUSION: Pterostilbene increases LDL and reduces blood pressure in adults. This trial is registered with Clinicaltrials.gov NCT01267227.